The small molecule PSMA-617 labeled with lutetium-177 (177Lu) (a low linear energy transfer (LET) β- emitter) has been reported to decrease tumoral burden of metastatic, castration resistant prostate cancer with limited systemic side effects (13–15). Here, FOLH1 is linked to prostate cancer.